The term liquid biopsy has been part of the oncology research vocabulary for more than twenty years and is now moving into clinical cancer diagnostics. For much of that time, however, it remained largely within the academic research space, where scientists explored whether tumour-derived biomarkers could be detected in blood and other biofluids [1,2].
Over the past several years, that idea has started to move into real clinical practice [1,3] advances in sequencing technologies, molecular detection methods and analytical tools are now making it possible to detect genomic alterations that were simply too difficult to measure before [2,4]. As a result, liquid biopsy is beginning to influence how clinicians understand and manage cancer [3].
I was reminded of how quickly the field is evolving when I recently attended the BloodPAC consortium meeting in San Diego. What struck me most was the level of collaboration in the room. Researchers, diagnostic developers, pharmaceutical companies, technology providers and regulators were all sitting together discussing how to move the field forward.
Many of these organizations compete in the marketplace. But during these discussions the focus wasn’t on competition – it was on solving the scientific and technical challenges that still stand between promising technology and reliable clinical tools.
One theme that came up repeatedly was the importance of analytical validation and reproducibility. A few years ago, the conversation centred on what liquid biopsy might make possible. Today the focus is on ensuring results are consistent across platforms, laboratories and clinical studies.
That shift says something important about where the field is today. Liquid biopsy is moving from discovery toward becoming a practical component of precision oncology.
Beyond Blood: Expanding Liquid Biopsy Sample Types
When people hear the term liquid biopsy, they often think of blood-based testing. Blood is still the most widely used sample type, but the concept is broader than that [2,5].
Researchers are also studying other biofluids – including urine, sputum and cerebrospinal fluid – to better understand tumour biology in different clinical settings [5].
What these approaches share is the same technical challenge: detecting extremely small signals within complex biological samples [2,4].
Tumour-derived DNA – often referred to as circulating tumour DNA (ctDNA) – can represent only a tiny fraction of the total cell-free DNA (cfDNA) present in a sample, sometimes well under one percent [2,4]. Detecting these rare variants requires highly sensitive molecular technologies as well as careful control of pre-analytical variables [4].
As liquid biopsy becomes more integrated into clinical care, achieving consistent performance across laboratories will be essential.
A Field Shaped by Data
Another theme that surfaced during the BloodPAC discussions was the growing role of data analysis.
Liquid biopsy technologies generate enormous amounts of molecular information, and interpreting those data has become just as important as detecting the signals themselves [6].
Artificial intelligence (AI) and advanced computational tools are helping researchers identify patterns in complex genomic datasets and separate meaningful signals from background noise [2,4]. In many ways, liquid biopsy is becoming both a molecular biology challenge and a data science challenge.
The combination of sensitive molecular detection and advanced computational analysis is opening new possibilities for earlier detection and more precise monitoring of disease.
Why Collaboration Matters
As the science grows more sophisticated, it has become clear that no single organization can address these challenges alone.
The Blood Profiling Atlas in Cancer (BloodPAC) Consortium brings together academic institutions, diagnostic companies, pharmaceutical organizations, technology providers and regulators to address many of the scientific and technical hurdles facing liquid biopsy [7].
Participants include groups such as Memorial Sloan Kettering Cancer Center, the National Cancer Institute, AstraZeneca, Illumina, Guardant Health, GRAIL, Exact Sciences, Natera and the U.S. Food and Drug Administration.
The early years of liquid biopsy were defined by discovery. Today the focus is on validation, standardization and building the frameworks needed for these technologies to be trusted in clinical practice [3,7].
The Role of Enabling Technologies in Liquid Biopsy
Ultimately, the success of liquid biopsy depends on reliable molecular detection.
Whether a test analyses circulating tumour DNA in blood or biomarkers in another biofluid, identifying rare variants requires technologies capable of detecting extremely small signals with confidence.
At Meridian Life Science, much of our work focuses on supporting this molecular detection layer. Our genotyping technologies and molecular reagents are designed to help researchers and diagnostic developers detect genetic variants with the sensitivity and reproducibility required for modern molecular diagnostics.
These tools may not always be visible to clinicians or patients, but they form part of the infrastructure that helps make liquid biopsy testing possible.
Looking Ahead
Leaving the BloodPAC meeting, one impression stood out clearly: the liquid biopsy field has moved beyond its early discovery phase.
The focus now is on building the scientific and technical foundations that will allow these technologies to become part of routine clinical care. That includes improving analytical performance, establishing standards across laboratories, and developing frameworks that support regulatory confidence.
As advances in molecular technologies, computational analysis and collaborative science continue to converge, liquid biopsy is poised to play an even larger role in how cancer is detected, monitored and understood.
Turning these advances into reliable clinical tools requires expertise in biomarker science, molecular assay development and diagnostic reagents.
References:
1. Wan, J.C.M. et al. (2017). Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nature Reviews Cancer.
2. Heitzer, E., Ulz, P., & Geigl, J. (2015). Circulating tumor DNA as a liquid biopsy for cancer. Clinical Chemistry.
3. Merker, J.D. et al. (2022). Circulating Tumor DNA Analysis in Patients with Cancer. JAMA Oncology.
4. Li, M. et al. (2005). BEAMing up for detection and quantification of rare sequence variants. Nature Methods.
5. Crowley, E. et al. (2013). Liquid biopsy: monitoring cancer genetics in the blood. Nature Reviews Clinical Oncology.
6. Liu, M.C. et al. (2020). Sensitive and specific multi-cancer detection using circulating cell-free DNA. Annals of Oncology.
7. BloodPAC Consortium publications and resources. https://www.bloodpac.org
